Infectious Diseases Working Party (IDWP)
COVID-19
Study type:
Study number:
8414145
Type of treatment:
Allogeneic
Autologous
Diseases:
Complications: infectious
Short title:
Deferral survey
Primary objective:
Assess the current clinical practice in HCT/hematology centers with respect to attitude to deferral of HCT/chemotherapy in patients with hematological malignancies or undergoing HCT in case of asymptomatic patients with positive PCR assay
Key inclusion criteria:
Country:
All EBMT member countries
Principal investigator:
Jan Styczynski
EBMT Study coordinator:
Nina Knelange
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
Centers’ contact / Centers’ policies
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results